Molecular imaging and targeted therapies in oncology: New concepts in treatment response assessment. A collection of cases

Maria A. Pantaleo, M. Nannini, E. Lopci, P. Castelucci, A. Maleddu, F. Lodi, C. Nanni, V. Allegri, M. Astorino, G. Brandi, M. Di Battista, S. Boschi, S. Fanti, G. Biasco

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The widespread use of several new non-cytotoxic drugs and the significant improvements in functional imaging highlights a number of difficulties in monitoring, interpreting and predicting treatment response in clinical practice. Certain guidelines for disease assessment after therapy are already available: the traditional Response Evaluation Criteria in Solid Tumours guidelines based on tumour size variations using conventional imaging technologies, the recent combined method developed by Choi and colleagues in gastrointestinal stromal tumour treated with tyrosine kinase inhibitors based on tumour density variations using computed tomography (CT), and the European Organization for Research and Treatment of Cancer criteria based on tumour glucose metabolism variations using fluorodeoxyglucose (FDG) positron emission tomography (PET). At the moment combined PET/CT response criteria are still not available. A number of new PET compounds other than FDG are also currently being developed to visualize specific cellular and molecular tumour pathways but their role in assessment and prediction of cancer treatment response has not yet been thoroughly investigated in a large series. However, in clinical practice many oncologists treat cancer patients with targeted therapies or chemotherapy and evaluate the response using conventional or functional imaging without appropriate and standardized guidelines. The aim of this study was to present a selection of clinical cases that illustrate the usefulness of new PET tracers and efficacy evaluation of new drugs. In the era of molecular imaging and molecular therapies, these cases highlight the urgency to develop new criteria for treatment assessment and the exigency of correctly interpreting the biological information obtained from new technologies, and introduce new concepts that require further investigation in clinical trials.

Original languageEnglish
Pages (from-to)443-452
Number of pages10
JournalInternational Journal of Oncology
Volume33
Issue number3
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Molecular Targeted Therapy
Molecular Imaging
Neoplasms
Positron-Emission Tomography
Guidelines
Therapeutics
Technology
Drug Evaluation
Gastrointestinal Stromal Tumors
Protein-Tyrosine Kinases
Tomography
Clinical Trials
Glucose
Drug Therapy

Keywords

  • C-choline PET
  • C-methionine PET
  • Ga-DOTA-NOC PET
  • Bevacizumab
  • PET
  • Response evaluation criteria in solid tumors
  • Sunitinib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Molecular imaging and targeted therapies in oncology : New concepts in treatment response assessment. A collection of cases. / Pantaleo, Maria A.; Nannini, M.; Lopci, E.; Castelucci, P.; Maleddu, A.; Lodi, F.; Nanni, C.; Allegri, V.; Astorino, M.; Brandi, G.; Di Battista, M.; Boschi, S.; Fanti, S.; Biasco, G.

In: International Journal of Oncology, Vol. 33, No. 3, 09.2008, p. 443-452.

Research output: Contribution to journalArticle

Pantaleo, MA, Nannini, M, Lopci, E, Castelucci, P, Maleddu, A, Lodi, F, Nanni, C, Allegri, V, Astorino, M, Brandi, G, Di Battista, M, Boschi, S, Fanti, S & Biasco, G 2008, 'Molecular imaging and targeted therapies in oncology: New concepts in treatment response assessment. A collection of cases', International Journal of Oncology, vol. 33, no. 3, pp. 443-452. https://doi.org/10.3892/ijo_00000026
Pantaleo, Maria A. ; Nannini, M. ; Lopci, E. ; Castelucci, P. ; Maleddu, A. ; Lodi, F. ; Nanni, C. ; Allegri, V. ; Astorino, M. ; Brandi, G. ; Di Battista, M. ; Boschi, S. ; Fanti, S. ; Biasco, G. / Molecular imaging and targeted therapies in oncology : New concepts in treatment response assessment. A collection of cases. In: International Journal of Oncology. 2008 ; Vol. 33, No. 3. pp. 443-452.
@article{ddf6eb9aa2c74cdaa14395a2834526c2,
title = "Molecular imaging and targeted therapies in oncology: New concepts in treatment response assessment. A collection of cases",
abstract = "The widespread use of several new non-cytotoxic drugs and the significant improvements in functional imaging highlights a number of difficulties in monitoring, interpreting and predicting treatment response in clinical practice. Certain guidelines for disease assessment after therapy are already available: the traditional Response Evaluation Criteria in Solid Tumours guidelines based on tumour size variations using conventional imaging technologies, the recent combined method developed by Choi and colleagues in gastrointestinal stromal tumour treated with tyrosine kinase inhibitors based on tumour density variations using computed tomography (CT), and the European Organization for Research and Treatment of Cancer criteria based on tumour glucose metabolism variations using fluorodeoxyglucose (FDG) positron emission tomography (PET). At the moment combined PET/CT response criteria are still not available. A number of new PET compounds other than FDG are also currently being developed to visualize specific cellular and molecular tumour pathways but their role in assessment and prediction of cancer treatment response has not yet been thoroughly investigated in a large series. However, in clinical practice many oncologists treat cancer patients with targeted therapies or chemotherapy and evaluate the response using conventional or functional imaging without appropriate and standardized guidelines. The aim of this study was to present a selection of clinical cases that illustrate the usefulness of new PET tracers and efficacy evaluation of new drugs. In the era of molecular imaging and molecular therapies, these cases highlight the urgency to develop new criteria for treatment assessment and the exigency of correctly interpreting the biological information obtained from new technologies, and introduce new concepts that require further investigation in clinical trials.",
keywords = "C-choline PET, C-methionine PET, Ga-DOTA-NOC PET, Bevacizumab, PET, Response evaluation criteria in solid tumors, Sunitinib",
author = "Pantaleo, {Maria A.} and M. Nannini and E. Lopci and P. Castelucci and A. Maleddu and F. Lodi and C. Nanni and V. Allegri and M. Astorino and G. Brandi and {Di Battista}, M. and S. Boschi and S. Fanti and G. Biasco",
year = "2008",
month = "9",
doi = "10.3892/ijo_00000026",
language = "English",
volume = "33",
pages = "443--452",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Molecular imaging and targeted therapies in oncology

T2 - New concepts in treatment response assessment. A collection of cases

AU - Pantaleo, Maria A.

AU - Nannini, M.

AU - Lopci, E.

AU - Castelucci, P.

AU - Maleddu, A.

AU - Lodi, F.

AU - Nanni, C.

AU - Allegri, V.

AU - Astorino, M.

AU - Brandi, G.

AU - Di Battista, M.

AU - Boschi, S.

AU - Fanti, S.

AU - Biasco, G.

PY - 2008/9

Y1 - 2008/9

N2 - The widespread use of several new non-cytotoxic drugs and the significant improvements in functional imaging highlights a number of difficulties in monitoring, interpreting and predicting treatment response in clinical practice. Certain guidelines for disease assessment after therapy are already available: the traditional Response Evaluation Criteria in Solid Tumours guidelines based on tumour size variations using conventional imaging technologies, the recent combined method developed by Choi and colleagues in gastrointestinal stromal tumour treated with tyrosine kinase inhibitors based on tumour density variations using computed tomography (CT), and the European Organization for Research and Treatment of Cancer criteria based on tumour glucose metabolism variations using fluorodeoxyglucose (FDG) positron emission tomography (PET). At the moment combined PET/CT response criteria are still not available. A number of new PET compounds other than FDG are also currently being developed to visualize specific cellular and molecular tumour pathways but their role in assessment and prediction of cancer treatment response has not yet been thoroughly investigated in a large series. However, in clinical practice many oncologists treat cancer patients with targeted therapies or chemotherapy and evaluate the response using conventional or functional imaging without appropriate and standardized guidelines. The aim of this study was to present a selection of clinical cases that illustrate the usefulness of new PET tracers and efficacy evaluation of new drugs. In the era of molecular imaging and molecular therapies, these cases highlight the urgency to develop new criteria for treatment assessment and the exigency of correctly interpreting the biological information obtained from new technologies, and introduce new concepts that require further investigation in clinical trials.

AB - The widespread use of several new non-cytotoxic drugs and the significant improvements in functional imaging highlights a number of difficulties in monitoring, interpreting and predicting treatment response in clinical practice. Certain guidelines for disease assessment after therapy are already available: the traditional Response Evaluation Criteria in Solid Tumours guidelines based on tumour size variations using conventional imaging technologies, the recent combined method developed by Choi and colleagues in gastrointestinal stromal tumour treated with tyrosine kinase inhibitors based on tumour density variations using computed tomography (CT), and the European Organization for Research and Treatment of Cancer criteria based on tumour glucose metabolism variations using fluorodeoxyglucose (FDG) positron emission tomography (PET). At the moment combined PET/CT response criteria are still not available. A number of new PET compounds other than FDG are also currently being developed to visualize specific cellular and molecular tumour pathways but their role in assessment and prediction of cancer treatment response has not yet been thoroughly investigated in a large series. However, in clinical practice many oncologists treat cancer patients with targeted therapies or chemotherapy and evaluate the response using conventional or functional imaging without appropriate and standardized guidelines. The aim of this study was to present a selection of clinical cases that illustrate the usefulness of new PET tracers and efficacy evaluation of new drugs. In the era of molecular imaging and molecular therapies, these cases highlight the urgency to develop new criteria for treatment assessment and the exigency of correctly interpreting the biological information obtained from new technologies, and introduce new concepts that require further investigation in clinical trials.

KW - C-choline PET

KW - C-methionine PET

KW - Ga-DOTA-NOC PET

KW - Bevacizumab

KW - PET

KW - Response evaluation criteria in solid tumors

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=54849188700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54849188700&partnerID=8YFLogxK

U2 - 10.3892/ijo_00000026

DO - 10.3892/ijo_00000026

M3 - Article

C2 - 18695872

AN - SCOPUS:54849188700

VL - 33

SP - 443

EP - 452

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -